The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.
This report provides:
An overview of the global markets and technologies for cancer vaccines.
Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of CAGRs through 2021.
Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
Examination of the governmental and regulatory environment and how its effecting the market.
Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
Relevant patent analysis, presented by year and by vaccine type.
The scope of this study entails the global market of cancer vaccines. The report covers the total market of cancer vaccines, which includes two main areas of applications, prophylactic vaccines and therapeutic vaccines. Human papillomavirus (HPV) vaccines and hepatitis B vaccines that indirectly act against cancer are also included in the report.